ATE260652T1 - Arzneimittel und verfahren zur behandlung von aufmerksamkeitsstörungen und aufmerksamkeits- /hyperaktivitätsstörungen mit methylphenidat - Google Patents

Arzneimittel und verfahren zur behandlung von aufmerksamkeitsstörungen und aufmerksamkeits- /hyperaktivitätsstörungen mit methylphenidat

Info

Publication number
ATE260652T1
ATE260652T1 AT98963170T AT98963170T ATE260652T1 AT E260652 T1 ATE260652 T1 AT E260652T1 AT 98963170 T AT98963170 T AT 98963170T AT 98963170 T AT98963170 T AT 98963170T AT E260652 T1 ATE260652 T1 AT E260652T1
Authority
AT
Austria
Prior art keywords
attention
disorders
methylphenidate
treatment
methods
Prior art date
Application number
AT98963170T
Other languages
English (en)
Inventor
Juan Mantelle
Terese A Dixon
Original Assignee
Noven Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26750154&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE260652(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Noven Pharma filed Critical Noven Pharma
Application granted granted Critical
Publication of ATE260652T1 publication Critical patent/ATE260652T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
AT98963170T 1997-12-15 1998-12-14 Arzneimittel und verfahren zur behandlung von aufmerksamkeitsstörungen und aufmerksamkeits- /hyperaktivitätsstörungen mit methylphenidat ATE260652T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6951097P 1997-12-15 1997-12-15
US09/163,351 US6210705B1 (en) 1997-12-15 1998-09-30 Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
PCT/US1998/026560 WO1999030694A2 (en) 1997-12-15 1998-12-14 Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate

Publications (1)

Publication Number Publication Date
ATE260652T1 true ATE260652T1 (de) 2004-03-15

Family

ID=26750154

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98963170T ATE260652T1 (de) 1997-12-15 1998-12-14 Arzneimittel und verfahren zur behandlung von aufmerksamkeitsstörungen und aufmerksamkeits- /hyperaktivitätsstörungen mit methylphenidat

Country Status (28)

Country Link
US (2) US6210705B1 (de)
EP (2) EP2314288B1 (de)
JP (3) JP4316800B2 (de)
KR (1) KR100633348B1 (de)
CN (1) CN1368876A (de)
AR (1) AR014062A1 (de)
AT (1) ATE260652T1 (de)
AU (1) AU752027B2 (de)
BR (1) BR9814282A (de)
CA (1) CA2315237C (de)
CZ (2) CZ300535B6 (de)
DE (1) DE69822199T2 (de)
DK (1) DK1037615T3 (de)
ES (2) ES2452517T3 (de)
HK (1) HK1049447A1 (de)
HU (1) HU226615B1 (de)
IL (1) IL136760A0 (de)
LV (1) LV12558B (de)
NO (1) NO329974B1 (de)
NZ (1) NZ505689A (de)
PE (1) PE20000120A1 (de)
PL (1) PL195315B1 (de)
PT (1) PT1037615E (de)
RU (1) RU2233156C2 (de)
SI (1) SI20360B (de)
TR (1) TR200001736T2 (de)
TW (2) TWI242452B (de)
WO (1) WO1999030694A2 (de)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
US20020102291A1 (en) * 1997-12-15 2002-08-01 Noven Pharmaceuticals, Inc. Compositions and method for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
GB9913458D0 (en) * 1999-06-09 1999-08-11 Medeva Europ Ltd The therapeutic use of d-threo-methylphenidate
GB9918735D0 (en) * 1999-08-09 1999-10-13 Straken Limited Transdermal patches
CO5261532A1 (es) * 1999-11-15 2003-03-31 Novartis Ag Compuestos heterociclicos sililados, procedimiento para la preparacion de estos y composicion farmaceutica que los contiene
ES2210025T3 (es) * 1999-12-17 2004-07-01 Celltech Pharma Europe Limited Agente farmaceutico para el tratamiento de estados convulsivos.
US6455066B1 (en) 2000-03-10 2002-09-24 Epicept Corporation Intradermal-penetration agents for topical local anesthetic administration
US6905016B2 (en) * 2000-03-14 2005-06-14 Noven Pharmaceuticals, Inc. Packaging system for transdermal drug delivery systems
US7674480B2 (en) * 2000-06-23 2010-03-09 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
US20020119187A1 (en) * 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
DE10060550C1 (de) * 2000-12-06 2002-04-18 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit dem Wirkstoff Oxybutynin und Verfahren zur Herstellung Oxybutynin enthaltender Wirkstoffschichten
EP1366762B1 (de) * 2001-03-07 2015-12-30 Hisamitsu Pharmaceutical Co., Inc. Klebendes pflaster
FR2822049B1 (fr) * 2001-03-13 2003-08-01 Dbv Medica 1 Patch destine notamment a depister l'etat de sensibilisation d'un sujet a un allergene, procede de fabrication et utilisation
NZ528148A (en) * 2001-03-16 2006-02-24 Alza Corp Transdermal patch for administering fentanyl
US20050208117A1 (en) * 2001-03-16 2005-09-22 Venkatraman Subramanian S Transdermal administration of fentanyl and analogs thereof
DE10141652B4 (de) * 2001-08-24 2011-04-07 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System auf der Basis von Polyacrylat-Haftklebern ohne funktionelle Gruppen und seine Verwendung
DE10141650C1 (de) * 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
US20030049272A1 (en) * 2001-08-30 2003-03-13 Yatindra Joshi Pharmaceutical composition which produces irritation
JP4354678B2 (ja) * 2002-08-28 2009-10-28 久光製薬株式会社 貼付剤
US6913768B2 (en) 2002-09-24 2005-07-05 Shire Laboratories, Inc. Sustained release delivery of amphetamine salts
CN101797221B (zh) 2002-12-13 2013-06-12 杜雷科特公司 包含高粘度液体载体材料的口服递药系统
JP2007509951A (ja) * 2003-10-28 2007-04-19 ノーヴェン ファーマシューティカルズ インコーポレイテッド 経皮的なドラッグデリバリーシステムにおける医薬品の損失及び送達を制御するための組成物及び方法
JP5271540B2 (ja) 2005-01-20 2013-08-21 インスティチュート フォー モレキュラー メディスン インコーポレイテッド メチルフェニデート誘導体を含む治療剤及び医薬組成物
HRP20110779T1 (hr) * 2005-01-20 2011-12-31 Institute For Molecular Medicine Upotrebe derivata metilfenidata
DK1962815T3 (da) * 2005-12-23 2010-11-15 Epinamics Gmbh Anvendelse af filmdannende hårplejepolymerer fra gruppen polyurethaner og farmaceutiske tilberedninger og plastre indeholdende nævnte polymerer
US9393218B2 (en) * 2005-12-23 2016-07-19 Epinamics Gmbh Use of film-forming hair care polymers from the group of polyurethanes and pharmaceutical preparations and patches that contain these polymers
US8715723B2 (en) * 2006-02-27 2014-05-06 Noven Pharmaceuticals, Inc. Compositions and methods for delivery of amino-functional drugs
DE602007010119D1 (de) * 2006-05-01 2010-12-09 Colgate Palmolive Co Mundpflegezusammensetzung mit silikonverbund
US20100104621A1 (en) * 2007-02-21 2010-04-29 Connected Health Systems, Llc Treating adhd and other diseases involving inflammation
MY162831A (en) * 2007-10-15 2017-07-31 Alza Corp Once-a-day replacement transdermal administration of fentanyl
FR2924349B1 (fr) 2007-12-03 2010-01-01 Dbv Tech Methode de desensibilitation aux allergenes
FR2924350B1 (fr) * 2007-12-03 2010-08-13 Dbv Tech Procede et compositions pour la vaccination par voie cutanee
WO2009075782A1 (en) 2007-12-06 2009-06-18 Durect Corporation Methods useful for the treatment of pain, arthritic conditions, or inflammation associated with a chronic condition
AU2008346830B2 (en) * 2007-12-31 2014-07-24 Acclarent, Inc. Mucosal tissue dressing and method of use
FR2926466B1 (fr) * 2008-01-23 2010-11-12 Dbv Tech Procede de fabrication de patchs par electrospray
WO2009146320A1 (en) 2008-05-27 2009-12-03 Dmi Life Sciences, Inc. Therapeutic methods and compounds
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
JP5155128B2 (ja) * 2008-12-11 2013-02-27 日東電工株式会社 メチルフェニデート貼付製剤
EP2631069B1 (de) * 2009-06-05 2014-11-05 Megtec Systems, Inc. Anordnungskanal geeignet um in einen Schwebebalken eingesetzt zu werden und Verfahren, um den Luftstrom in den Anordnungskanal einzustellen.
EP2364695A1 (de) 2010-02-10 2011-09-14 Nitto Denko Corporation Methylphenidat-Flickenherstellung
US20110200663A1 (en) * 2010-02-12 2011-08-18 Nitto Denko Corporation Methylphenidate patch preparation
US9119809B2 (en) 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10905652B2 (en) 2011-03-23 2021-02-02 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9603809B2 (en) 2011-03-23 2017-03-28 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US10292937B2 (en) 2011-03-23 2019-05-21 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US9283214B2 (en) 2011-03-23 2016-03-15 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
DK4011364T3 (da) 2011-03-23 2024-03-18 Ironshore Pharmaceuticals & Dev Inc Fremgangsmåder og sammensætninger til behandling af ADD (Attention Deficit Disorder)
US8927010B2 (en) 2011-03-23 2015-01-06 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US8916588B2 (en) 2011-03-23 2014-12-23 Ironshore Pharmaceuticals & Development, Inc. Methods for treatment of attention deficit hyperactivity disorder
US9498447B2 (en) 2011-03-23 2016-11-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US11241391B2 (en) 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
KR101616111B1 (ko) * 2011-07-28 2016-04-27 켐팜 인코포레이티드 메틸페니데이트 프로드러그, 이의 제조 방법 및 사용 방법
CA2891467A1 (en) 2012-10-15 2014-04-24 Noven Pharmaceuticals, Inc. Compositions and methods for the transdermal delivery of methylphenidate
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
ES2864327T3 (es) 2012-12-28 2021-10-13 Noven Pharma Composiciones de múltiples polímeros para la administración transdérmica de fármacos
AR094289A1 (es) 2012-12-28 2015-07-22 Noven Pharma Sistemas de administracion transdermica de farmacos para levonorgestrel y etinil estradiol
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
US11337936B2 (en) 2013-03-14 2022-05-24 Noven Pharmaceuticals, Inc. Amphetamine transdermal compositions with acrylic block copolymer
AR095260A1 (es) 2013-03-15 2015-09-30 Noven Pharma Composiciones de anfetaminas transdérmicas estables y métodos de fabricación
TW201521769A (zh) 2013-03-15 2015-06-16 Durect Corp 具有流變改質劑以減少溶解變異性之組成物
AR095259A1 (es) 2013-03-15 2015-09-30 Noven Pharma Composiciones y métodos para la administración transdérmica de fármacos de amina terciaria
AU2014371437B2 (en) 2013-12-25 2020-01-30 Fujimoto Co., Ltd. Prophylactic and therapeutic agent for attention-deficit/hyperactivity disorder
US9980921B2 (en) * 2016-06-30 2018-05-29 Taho Pharmaceuticals Ltd. Transdermal delivery system containing methylphenidate or its salts and methods thereof
MY205229A (en) 2016-07-06 2024-10-08 Durect Corp Oral dosage form with drug composition, barrier layer and drug layer
CN106511264A (zh) * 2016-11-15 2017-03-22 北京万全德众医药生物技术有限公司 一种盐酸哌甲酯口服溶液剂及其制备方法
EP3551619B1 (de) 2016-12-11 2024-03-06 Zevra Therapeutics, Inc. Zusammensetzungen mit methylphenidat-prodrugs, verfahren zur herstellung und verwendung davon
EP3598982A1 (de) 2018-07-23 2020-01-29 Centre National De La Recherche Scientifique Biokonjugate von neuropeptidenderivaten
JP7600661B2 (ja) * 2020-12-11 2024-12-17 ａｒｔｉｅｎｃｅ株式会社 貼付剤

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2957880A (en) 1953-12-23 1960-10-25 Ciba Pharm Prod Inc Process for the conversion of stereoisomers
US4310509A (en) 1979-07-31 1982-01-12 Minnesota Mining And Manufacturing Company Pressure-sensitive adhesive having a broad spectrum antimicrobial therein
US4655767A (en) 1984-10-29 1987-04-07 Dow Corning Corporation Transdermal drug delivery devices with amine-resistant silicone adhesives
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5474783A (en) 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
DE3910578A1 (de) * 1989-03-29 1990-10-04 Schering Ag Mittel zur transdermalen applikation enthaltend gestoden
JP2693212B2 (ja) * 1989-03-28 1997-12-24 日東電工株式会社 疾患治療用テープ製剤
WO1992021333A2 (en) * 1991-05-24 1992-12-10 Pharmavene, Inc. Treatment of drug withdrawal symptoms and drug craving with type b monoamine oxidase inhibitors
US5629019A (en) 1992-02-27 1997-05-13 Alza Corporation Formulations with hydrophobic permeation enhancers
HK1006281A1 (en) 1992-07-28 1999-02-19 The Procter & Gamble Company Pharmaceutical composition for topical use containing a crosslinked cationic polymer and an alkoxylated ether
CH691209A5 (de) 1993-09-06 2001-05-15 Scherrer Inst Paul Herstellungsverfahren für einen Polmerelektrolyten und elektrochemische Zelle mit diesem Polymerelektrolyten.
DE59507025D1 (de) 1994-06-29 1999-11-18 Hennecke Gmbh Verfahren und Vorrichtung zum kontinuierlichen Herstellen von Schaumstoffblöcken oder Schaumstoffbahnen
US5601839A (en) 1995-04-26 1997-02-11 Theratech, Inc. Triacetin as a penetration enhancer for transdermal delivery of a basic drug
US5780050A (en) 1995-07-20 1998-07-14 Theratech, Inc. Drug delivery compositions for improved stability of steroids
AU2590697A (en) 1997-03-07 1998-09-22 Richard R. Jackson Anesthetizing plastics, drug delivery plastics, and related medical products, s ystems and methods
GB9711032D0 (en) 1997-05-30 1997-07-23 Johnson Matthey Plc Compound as a stimulant for the central nervous system
EP1239219A4 (de) 1999-12-15 2003-03-12 Osaka Gas Co Ltd Flüssigkeitsverteiler, brennvorrichtung, gasturbinentriebwerk und wärmekraftsystem

Also Published As

Publication number Publication date
US6348211B1 (en) 2002-02-19
SI20360A (sl) 2001-04-30
LV12558B (en) 2001-03-20
HUP0004539A2 (hu) 2001-06-28
NO20003096L (no) 2000-08-15
KR100633348B1 (ko) 2006-10-16
PE20000120A1 (es) 2000-02-19
ES2452517T3 (es) 2014-04-01
NO329974B1 (no) 2011-01-31
NZ505689A (en) 2003-01-31
AR014062A1 (es) 2001-01-31
CZ20002209A3 (cs) 2000-11-15
HUP0004539A3 (en) 2006-06-28
HK1156872A1 (en) 2012-06-22
ES2219926T3 (es) 2004-12-01
US6210705B1 (en) 2001-04-03
CN1368876A (zh) 2002-09-11
WO1999030694A3 (en) 1999-08-19
DE69822199D1 (de) 2004-04-08
PL341596A1 (en) 2001-04-23
RU2233156C2 (ru) 2004-07-27
EP2314288A1 (de) 2011-04-27
SI20360B (sl) 2008-06-30
WO1999030694A2 (en) 1999-06-24
DE69822199T2 (de) 2005-02-17
EP1037615A2 (de) 2000-09-27
CA2315237C (en) 2009-12-01
DK1037615T3 (da) 2004-07-12
BR9814282A (pt) 2000-10-03
TR200001736T2 (tr) 2001-01-22
JP2002510600A (ja) 2002-04-09
EP2314288B1 (de) 2013-12-11
HU226615B1 (en) 2009-04-28
IL136760A0 (en) 2001-06-14
CA2315237A1 (en) 1999-06-24
PL195315B1 (pl) 2007-08-31
CZ300535B6 (cs) 2009-06-10
KR20010033114A (ko) 2001-04-25
JP4316800B2 (ja) 2009-08-19
CZ2009132A3 (cs) 2016-03-23
AU1824999A (en) 1999-07-05
JP2009073856A (ja) 2009-04-09
TWI242452B (en) 2005-11-01
AU752027B2 (en) 2002-09-05
LV12558A (lv) 2000-11-20
NO20003096D0 (no) 2000-06-15
TW200406231A (en) 2004-05-01
TWI244396B (en) 2005-12-01
CZ305817B6 (cs) 2016-03-23
JP2013056944A (ja) 2013-03-28
PT1037615E (pt) 2004-07-30
HK1049447A1 (zh) 2003-05-16
EP1037615B1 (de) 2004-03-03

Similar Documents

Publication Publication Date Title
ATE260652T1 (de) Arzneimittel und verfahren zur behandlung von aufmerksamkeitsstörungen und aufmerksamkeits- /hyperaktivitätsstörungen mit methylphenidat
ATE275383T1 (de) Oxadisäuren und verwandte verbindungen zur behandlung von hautstörungen
DE60023128D1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
DE69836752D1 (de) Prostaglandinagoniste und deren verwendung zur behandlung von knochenerkrankungen
DE69622074D1 (de) Cystin-Silikon-Copolymere und deren Verwendung zur Behandlung von keratinischen Materialien
EP1027016A4 (de) Verfahren und pharmazeutische zusammensetzungen zum verschluss von metzhautrissen
DE69829625D1 (de) Verfahren und Vorrichtung zur Behandlung von Perfluorokohlenstoff
DE69917625D1 (de) Implantate zur verabreichung von wirkstoffen und verfahren zum herstellen von implantaten
ATE255888T1 (de) Tetrahydronaphtalene verbindungen und deren verwendung zur behandlung von neurodegenerativen krankheiten
DE69332732D1 (de) Pharmazeutische Zusammensetzung und Methode zur Behandlung von Hyperlipidämie und Arterioskerose
DE60023873D1 (de) Mittel zur behandlung von erkrankungen der speiseröhre
ATE252901T1 (de) Arzneimittel zur behandlung von entzündlichen herzkrankheiten
DE69526437D1 (de) Transdermal verabreichbare zubereitung zur behandlung von störungen des harnlassens
ATE527022T1 (de) Verwendung von cyclooxygenase-2-inhibitoren zur behandlung und vorbeugung von tumoren, von tumor- abhängigen erkrankungen und kachexie
DE69806801D1 (de) Galenische präparation zur prävention und behandlung von hepatokarzinomen
ATE215373T1 (de) 21-hydro-6,19-oxidoprogesterone (21oh-60p) und deren verwendung als arzneimittel zur behandlung von glukokortikoidüberschuss
ATE295174T1 (de) Arzneimittel zur behandlung von bluthochdruck
DE69532066D1 (de) Arzneimittel zur Behandlung von Restenosis und Gefässsklerose
DE19580261D2 (de) Pharmazeutische Zubereitungen und Arzneistoffe zur Prävention und Behandlung endothelialer Dysfunktion
EP1487480A4 (de) Fusionsmoleküle und verfahren zur behandlung von immunkrankheiten
DE69620691D1 (de) Therapeutisches Mittel zur Behandlung der Hypercholesterinämie
DE69809284D1 (de) Immunomodulator mit anti-mikrobakteriellen und anti-mykobakteriellen eigenschaften, verfahren zu seiner herstellung und pharmazeutische zusammensetzungen zur behandlung von mykobakteriosen sowie von chronischen und nicht-spezifischen lungenzuständen, sexuell übertragbaren krankheiten und den daraus resultierenden immunschwächen
DE69841550D1 (de) Behandlung von fibromyalgie und verwandten erkrankungen
DE69838785D1 (de) Pharmazeutische mittel zur behandlung von zerebralen amyloidosis
ATE292457T1 (de) Mittel und verfahren zur transdermalen verabreichung säurelabiler arzneistoffe

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1037615

Country of ref document: EP

EENE Nomination of inventor